IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Shares Bought by Fisher Asset Management LLC

Fisher Asset Management LLC lifted its stake in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA) by 26.7% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 848,909 shares of the company’s stock after purchasing an additional 179,114 shares during the quarter. Fisher Asset Management LLC owned about 0.98% of IDEAYA Biosciences worth $26,893,000 at the end of the most recent reporting period.

Several other institutional investors have also bought and sold shares of the stock. SG Americas Securities LLC acquired a new stake in shares of IDEAYA Biosciences in the 1st quarter worth approximately $101,000. Vanguard Group Inc. raised its holdings in IDEAYA Biosciences by 19.6% during the first quarter. Vanguard Group Inc. now owns 4,155,757 shares of the company’s stock worth $182,355,000 after purchasing an additional 679,985 shares in the last quarter. O Shaughnessy Asset Management LLC acquired a new stake in IDEAYA Biosciences in the first quarter worth approximately $214,000. American International Group Inc. boosted its stake in IDEAYA Biosciences by 8.4% during the 1st quarter. American International Group Inc. now owns 32,430 shares of the company’s stock valued at $1,423,000 after purchasing an additional 2,514 shares in the last quarter. Finally, CANADA LIFE ASSURANCE Co increased its position in shares of IDEAYA Biosciences by 120.7% during the 1st quarter. CANADA LIFE ASSURANCE Co now owns 11,099 shares of the company’s stock valued at $487,000 after purchasing an additional 6,069 shares during the period. Institutional investors and hedge funds own 98.29% of the company’s stock.

Analysts Set New Price Targets

Several analysts have recently weighed in on the company. Royal Bank of Canada restated an “outperform” rating and issued a $61.00 price objective on shares of IDEAYA Biosciences in a report on Tuesday, September 24th. Leerink Partnrs lowered shares of IDEAYA Biosciences from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, November 5th. Wedbush reiterated an “outperform” rating and issued a $52.00 target price on shares of IDEAYA Biosciences in a report on Monday, November 4th. UBS Group began coverage on shares of IDEAYA Biosciences in a report on Thursday, October 24th. They set a “buy” rating and a $50.00 target price for the company. Finally, Oppenheimer restated an “outperform” rating and issued a $53.00 price target on shares of IDEAYA Biosciences in a research report on Tuesday, October 29th. Two analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $53.67.

IDEAYA Biosciences Trading Up 0.9 %

NASDAQ:IDYA opened at $26.78 on Wednesday. IDEAYA Biosciences, Inc. has a 1-year low of $25.20 and a 1-year high of $47.74. The firm has a market capitalization of $2.31 billion, a price-to-earnings ratio of -11.49 and a beta of 0.86. The business’s fifty day moving average price is $30.00 and its 200 day moving average price is $35.54.

IDEAYA Biosciences (NASDAQ:IDYA) last released its earnings results on Monday, November 4th. The company reported ($0.60) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.63) by $0.03. During the same quarter in the previous year, the company posted ($0.46) earnings per share. Equities analysts forecast that IDEAYA Biosciences, Inc. will post -2.46 earnings per share for the current year.

IDEAYA Biosciences Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.